ArticleTranslational pediatrics2025
Temporal trends in cross-country inequalities of neuroblastoma burden in children under 14 years of age from 1990 to 2021.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The burden of childhood cancers in the South Asian Association for Regional Cooperation (SAARC) Region: a population-based, cross-sectional GLOBOCAN 2022 analysis.The Lancet regional health. Southeast Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroblastoma is the most prevalent extracranial solid tumor in children. This study aims to assess the global burden of neuroblastoma in 2021. Methods: We utilized data from the Global Burden of Disease (GBD) 2021 study to collect the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of neuroblastoma, and calculated the estimated annual percentage change (EAPC). The neuroblastoma burden was then assessed using decomposition analysis and inequality analysis. Additionally, we forecast neuroblastoma trends from 2022 to 2036. Results: In 2021, an estimated 51,762 [95% uncertain interval (UI): 34,704.53-70,435.21] cases of neuroblastoma were reported globally among individuals under 14 years of age, with 5,560 (95% UI: 3,734.21-7,560.03) new cases and an estimated 1,977 (95% UI: 1,445.04-2,528.54) deaths. From 1990 to 2021, the global burden of neuroblastoma showed an upward trend. Only the high socio-demographic index (SDI) region exhibited a declining trend in disease burden, with an EAPC for incidence of -0.81 (-1.05 to -0.56). India had the highest number of new cases, total cases, and deaths among 204 countries. Decomposition analysis indicated that population growth and epidemiological changes are the primary drivers of the disease burden. Inequality analysis indicates an increasing burden of neuroblastoma in low-SDI countries. The actual number of cases is expected to continue increasing. By 2036, the age-standardized prevalence rate (ASPR) is projected to be 2.83 per 100,000 for males and 2.18 per 100,000 for females. Conclusions: This study highlights the increasing global neuroblastoma case numbers and the inequities in disease distribution. These insights may guide the development of more effective public health policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.